Novel suppressive effects of ketotifen on migration and invasion of MDA-MB-231 and HT-1080 cancer cells

Biomolecules and Therapeutics

Volumn 22, Issue 6, 2014, Pages 540-546

  Kim, Hyun Ji ^a   Park, Mi Kyung ^a   Kim, Soo Youl ^b   Lee, Chang Hoon ^a  

^a Dongguk University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

HT 1080; Invasion; Ketotifen; MDA MB 231; Migration

Indexed keywords

GELATINASE B; KETOTIFEN; PROTEIN CDC42; RAC PROTEIN; RHO FACTOR;

ARTICLE; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DEGRADATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBROSARCOMA CELL LINE; HT 1080 CELL LINE; HUMAN; HUMAN CELL; MDA MB 231 CELL LINE; PROTEIN EXPRESSION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84912565419     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2014.081     Document Type: Article

References (40)

1. Aspenstrom, P. (2004) Integration of signalling pathways regulated by small GTPases and calcium. Biochim. Biophys. Acta 1742, 51-58.
2. Bravo-Cordero, J. J., Hodgson, L. and Condeelis, J. (2012) Directed cell invasion and migration during metastasis. Curr. Opin. Cell Biol. 24, 277-283.
3. Bray, K., Gillette, M., Young, J., Loughran, E., Hwang, M., Sears, J. C. and Vargo-Gogola, T. (2013) Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res. 15, R91.
4. Brinckerhoff, C. E. and Matrisian, L. M. (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat.Rev. Mol. Cell Biol. 3, 207-214.
5. Cailleau, R., Young, R., Olive, M. and Reeves, W. J., Jr. (1974) Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53, 661- 674.
6. Cricco, G., Nunez, M., Medina, V., Garbarino, G., Mohamad, N., Gutierrez, A., Cocca, C., Bergoc, R., Rivera, E. and Martin, G. (2006) Histamine modulates cellular events involved in tumour invasiveness in pancreatic carcinoma cells. Inflamm.Res. 55 Suppl 1, S83- 84.
7. Ellenbroek, S. I. and Collard, J. G. (2007) Rho GTPases: functions and association with cancer. Clin. Exp. Metastasis 24, 657-672.
8. Elliott, R. L. (2012) Four lessons from global health drug discovery: medicine for an ailing industry? ACS Med. Chem. Lett. 3, 688-690.
9. Ferry, G., Boutin, J. A., Hennig, P., Genton, A., Desmet, C., Fauchere, J. L., Atassi, G. and Tucker, G. C. (1998) A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. Eur. J. Pharmacol. 351, 225-233.
10. Franzius, D., Hoth, M. and Penner, R. (1994) Non-specific effects of calcium entry antagonists in mast cells. Pflugers Arch. 428, 433- 438.
11. Friedl, P. and Wolf, K. (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3, 362-374.
12. Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M. and Kaina, B. (2002) Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br.J. Cancer 87, 635-644.
13. Fritz, G., Just, I. and Kaina, B. (1999) Rho GTPases are over-expressed in human tumors. Int. J.Cancer 81, 682-687.
14. Geiser, A. G., Anderson, M. J. and Stanbridge, E. J. (1989) Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49, 1572-1577.
15. Gommerman, J. L. and Berger, S. A. (1998) Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. Blood 91, 1891-1900.
16. Grahnen, A., Lonnebo, A., Beck, O., Eckernas, S. A., Dahlstrom, B. and Lindstrom, B. (1992) Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm. Drug Dispos. 13, 255-262.
17. Gschwandtner, M., Purwar, R., Wittmann, M., Baumer, W., Kietzmann, M., Werfel, T. and Gutzmer, R. (2008) Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J. Invest. Dermatol. 128, 2783-2791.
18. Gupta, S. C., Sung, B., Prasad, S., Webb, L. J. and Aggarwal, B. B. (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol. Sci. 34, 508-517.
19. Jung, K. H., Park, B. H. and Hong, S. S. (2012) Progress in cancer therapy targeting c-Met signaling pathway. Arch. Pharm. Res. 35, 595-604.
20. Kim, H. R., Kim, J. M., Kim, M. S., Hwang, J. K., Park, Y. J., Yang, S. H., Kim, H. J., Ryu, D. G., Lee, D. S., Oh, H., Kim, Y. C., Rhee, Y. J., Moon, B. S., Yun, J. M., Kwon, K. B. and Lee, Y. R. (2014) Saussurea lappa extract suppresses TPA-induced cell invasion via inhibition of NF-kappaB-dependent MMP-9 expression in MCF-7 breast cancer cells. BMC Complement. Altern. Med. 14, 170.
21. Kobayashi, K., Matsumoto, S., Morishima, T., Kawabe, T. and Okamoto, T. (2000) Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res. 60, 3978-3984.
22. Mazzocca, A. and Carloni, V. (2009) The metastatic process: methodological advances and pharmacological challenges. Curr. Med. Chem. 16, 1704-1717.
23. Medina, V., Croci, M., Crescenti, E., Mohamad, N., Sanchez-Jimenez, F., Massari, N., Nunez, M., Cricco, G., Martin, G., Bergoc, R. and Rivera, E. (2008) The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol. Ther. 7, 28-35.
24. Medina, V. A. and Rivera, E. S. (2010) Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 161, 755-767.
25. Mendoza, M. and Khanna, C. (2009) Revisiting the seed and soil in cancer metastasis. Int. J. Biochem. Cell Biol. 41, 1452-1462.
26. Meng, F., Han, Y., Staloch, D., Francis, T., Stokes, A. and Francis, H. (2011) The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology 54, 1718-1728.
27. Moore, D. H., Allison, B., Look, K. Y., Sutton, G. P. and Bigsby, R. M. (1997) Collagenase expression in ovarian cancer cell lines. Gynecol. Oncol. 65, 78-82.
28. Pacharn, P. and Vichyanond, P. (2013) Immunomodulators for conjunctivitis. Curr. Opin. Allergy Clin. Immunol. 13, 550-557.
29. Park, M. K., Jo, S. H., Lee, H. J., Kang, J. H., Kim, Y. R., Kim, H. J., Lee, E. J., Koh, J. Y., Ahn, K. O., Jung, K. C., Oh, S. H., Kim, S. Y. and Lee, C. H. (2013) Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells. Life Sci. 92, 154-160.
30. Park, M. K. and Lee, C. H. (2011) Alpinia katsumadai suppresses migration and 12-O-tetradecanoylphorbol-13-acetate-induced invasion of HT-1080 cells through suppression of transglutaminase-2, matrix metalloproteinase-2, and matrix metalloproteinase-9 expression. Cancer Prev. Res. 16, 326-332.
31. Parri, M. and Chiarugi, P. (2010) Rac and Rho GTPases in cancer cell motility control. Cell Commun. Signal. 8, 23.
32. Rasheed, S., Nelson-Rees, W. A., Toth, E. M., Arnstein, P. and Gardner, M. B. (1974) Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33, 1027-1033.
33. Schwarzer, G., Bassler, D., Mitra, A., Ducharme, F. M. and Forster, J. (2004) Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database Syst. Rev. CD001384.
34. Soboloff, J. and Berger, S. A. (2002) Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. J. Biol. Chem. 277, 13812-13820.
35. Soboloff, J., Zhang, Y., Minden, M. and Berger, S. A. (2002) Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging. Exp. Hematol. 30, 1219-1226.
36. Valastyan, S. and Weinberg, R. A. (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292.
37. Xu, D., McKee, C. M., Cao, Y., Ding, Y., Kessler, B. M. and Muschel, R. J. (2010) Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res. 70, 6988-6998.
38. Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J. and Grodzinski, P. (2012) Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin. Cancer Res. 18, 3229-3241.
39. Zhang, Y. and Berger, S. A. (2003) Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother. Pharmacol. 51, 407-414.
40. Zhang, Y., Crump, M. and Berge, S. A. (2002) Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death. Breast Cancer Res. Treat. 72, 265-278.